α-Helical CRF (9-41)

Research use only, not for human use.

α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo.

α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist. α-Helical Corticotropin Releasing Factor (9-41) decreases plasma growth hormone (GH) values in vivo.

———

α-Helical Corticotropin Releasing Factor (9-41) (10 μg; the third or lateral ventricle of the brain injection; once) significantly decreases plasma GH values.α-Helical Corticotropin Releasing Factor (9-41) (100 ng/kg; i.c.v. once) affects rhlL-1/β-induced enhancement of the splenic sympathetic activity.Animal Model:Adult Sprague-Dawley rats Dosage:10 μg Administration:The third or lateral ventricle of the brain injection; 10 μg once Result:Abolished the 10 min electroshocks-produced the decreasing of plasma GH levels by injected into the third or lateral ventricle of the brain 45 min before exposure to stress.Animal Model:Adult Sprague-Dawley rats with immunity of endogenous somatostatin (SS)Dosage:10 μg Administration:Lateral ventricle brain injection; 10 μg once Result:Showed no effect on plasma GH values in rats whose endogenous SS had been immunoneutralized, but did interfere with the stimulatory effect of GH-releasing factor (GRF).Animal Model:Male Wistar rats with rhlL-1/β injection Dosage:100 ng/kg Administration:Intracerebroventricularly injection; 100 ng/kg once Result:Completely blocked the rhlL-1/β-induced enhancement of the splenic sympathetic activity, but failed to alter the enhancement of nociceptive behaviors caused by rhlL-1/β.

———

Others

Other Targets

———

———

———

99658-03-4

3826.44

C166H274N46O53S2

>98% (HPLC)

———

———

——

(-20℃)

With Ice Pack

≥ 2 years